[go: up one dir, main page]

CR20160147A - FORMULATIONS OF ANTIBODIES - Google Patents

FORMULATIONS OF ANTIBODIES

Info

Publication number
CR20160147A
CR20160147A CR20160147A CR20160147A CR20160147A CR 20160147 A CR20160147 A CR 20160147A CR 20160147 A CR20160147 A CR 20160147A CR 20160147 A CR20160147 A CR 20160147A CR 20160147 A CR20160147 A CR 20160147A
Authority
CR
Costa Rica
Prior art keywords
antibodies
formulations
antibody crystals
antisclerous
formulas
Prior art date
Application number
CR20160147A
Other languages
Spanish (es)
Inventor
Christi L Clogston
Twinkle R Christian
Elisabeth Freeman
Timothy D Osslund
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45922852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160147(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20160147A publication Critical patent/CR20160147A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente se describen cristales de anticuerpos antiesclerosos, métodos para producir dichos cristales de anticuerpos y fórmulas que comprenden los cristales de anticuerpos.Antisclerous antibody crystals, methods for producing said antibody crystals and formulas comprising antibody crystals are described herein.

CR20160147A 2011-03-25 2012-03-23 FORMULATIONS OF ANTIBODIES CR20160147A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161467868P 2011-03-25 2011-03-25
PCT/US2012/030364 WO2012135035A1 (en) 2011-03-25 2012-03-23 Anti - sclerostin antibody crystals and formulations thereof

Publications (1)

Publication Number Publication Date
CR20160147A true CR20160147A (en) 2016-08-03

Family

ID=45922852

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160147A CR20160147A (en) 2011-03-25 2012-03-23 FORMULATIONS OF ANTIBODIES

Country Status (25)

Country Link
US (3) US9145457B2 (en)
EP (1) EP2688910B1 (en)
JP (2) JP2014511842A (en)
KR (1) KR20140018315A (en)
CN (1) CN103517920B (en)
AP (1) AP3981A (en)
AR (1) AR085575A1 (en)
AU (1) AU2012236962B2 (en)
BR (1) BR112013024493A2 (en)
CA (1) CA2830538C (en)
CL (1) CL2013002743A1 (en)
CO (1) CO6801637A2 (en)
CR (1) CR20160147A (en)
EA (1) EA029956B1 (en)
IL (1) IL228455A (en)
MA (1) MA35009B1 (en)
MX (1) MX338078B (en)
MY (1) MY170720A (en)
PE (1) PE20140437A1 (en)
PH (1) PH12013501971B1 (en)
SG (2) SG193610A1 (en)
TN (1) TN2013000378A1 (en)
TW (1) TW201247703A (en)
WO (1) WO2012135035A1 (en)
ZA (2) ZA201307122B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
AU2015331602A1 (en) * 2014-10-17 2017-04-27 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
AR103726A1 (en) 2015-02-27 2017-05-31 Merck Sharp & Dohme HUMAN ANTI-PD-1 MONOCLONAL ANTIBODY CRYSTALS
CN107090443B (en) * 2016-02-18 2020-12-08 中国农业大学 A method for preparing crystals of mitogen-activated protein kinase MoMps1 of oryzae oryzae
CN105777858B (en) * 2016-03-22 2019-09-10 东软威特曼生物科技(南京)有限公司 The compound stabilizer and its application method of Multiple Antibodies
WO2018013673A1 (en) 2016-07-13 2018-01-18 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN109952093B (en) * 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 A kind of SOST antibody pharmaceutical composition and use thereof
CN109112153A (en) * 2018-09-03 2019-01-01 浙江善测禾骑士生物科技有限公司 A kind of preparation method of LPOR-Y193F mutant protein crystal
US20210317215A1 (en) * 2018-10-31 2021-10-14 Merck Sharp & Dohme Corp. Anti-human pd-1 antibody crystals and methods of use thereof
KR20210089215A (en) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 Co-Formulation of Anti-LAG3 Antibody and Anti-PD-1 Antibody
EP3653702A1 (en) * 2018-11-15 2020-05-20 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Crystal structure of a replication protein encoded by a plasmid isolated from a multiple sclerosis patient
JP2022544495A (en) * 2019-08-12 2022-10-19 アムジエン・インコーポレーテツド Anti-sclerostin antibody formulation
JP7560038B2 (en) * 2020-04-06 2024-10-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Antibody preparations
CN113444800A (en) * 2021-06-30 2021-09-28 北京泱深生物信息技术有限公司 Application of gene group as co-prognostic factor in renal cancer prognosis detection
CN115804338A (en) * 2022-12-19 2023-03-17 新疆农业科学院经济作物研究所 Sea island cotton breeding method
CN118236484B (en) * 2022-12-23 2025-11-04 信立泰(苏州)药业有限公司 A Romosozumab antibody stabilizing agent, its preparation method and uses
CN116375864B (en) * 2023-05-16 2023-08-08 成都大熊猫繁育研究基地 Panda AMH-resistant monoclonal antibody, hybridoma cell strain and application thereof
WO2025030173A1 (en) * 2023-08-03 2025-02-06 Next Science IP Holdings Pty Ltd Reducing inflammation in surgical site tissues

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (en) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Device for the quantitative and qualitative detection of hydrocarbon-containing suspended particles in gases
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (en) 1990-07-26 2001-10-15 大正製薬株式会社 Stable aqueous liposome suspension
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2958076B2 (en) 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (en) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst Hiv-resistant recombined modified antibody and method for preparing modified antibody
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5864027A (en) 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
WO1995030003A2 (en) 1994-04-29 1995-11-09 Creative Biomolecules, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
CA2192821A1 (en) 1994-06-24 1996-01-04 Wayne R. Gombotz Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
DE4427221A1 (en) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induced osteoclast modulation for osteoporosis therapy
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1996039486A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human ccn-like growth factor
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9710811A (en) 1996-05-22 1999-08-17 Novopharm Biotech Inc Antigen-binding fragments that specifically detect nucleotide cancer cells that encode the fragments and their use for the prophylaxis and detection of cancer
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
CA2297109A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CA2361553A1 (en) 1999-01-29 2000-08-03 Zhenping Zhu Antibodies specific to kdr and uses thereof
EP1185642A2 (en) 1999-06-09 2002-03-13 Genentech, Inc. Compositions and methods for the treatment of tumor
AU2001241968B2 (en) 2000-03-02 2005-09-15 Amgen Inc. Chordin-like-2 molecules and uses thereof
MXPA02011808A (en) 2000-06-01 2003-04-10 Amgen Inc Cystine-knot polypeptides: cloaked-2 molecules and uses thereof.
US20040132021A1 (en) 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
CA2421056A1 (en) 2000-09-01 2002-03-28 Genentech, Inc. A polypeptide for use as a diagnostic marker for the presence of colon tumours
ES2332402T5 (en) 2000-10-12 2018-05-14 Genentech, Inc. Concentrated protein formulations of reduced viscosity
EP2325205A3 (en) 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (en) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA · 1 · -pyrrolines
AU2002357107B2 (en) 2001-12-06 2008-01-10 Biocontrol Systems, Inc. Sample collection and testing system
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
EP1575481A4 (en) 2002-03-01 2010-01-06 Celltech R & D Inc METHODS FOR INCREASING OR REDUCING BONE DENSITY
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
CA2504493C (en) 2002-11-01 2015-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
PL378566A1 (en) 2003-03-14 2006-05-02 Celltech R & D, Inc. Ligands for tgf-beta binding proteins and uses thereof
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (en) 2003-04-23 2009-08-04 Centro Inmunologia Molecular RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING GANGLIOSIDE N-GLICOLIL GM3 AND ITS USE FOR DIAGNOSIS AND TUMOR TREATMENT
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
ES2531155T3 (en) * 2004-07-23 2015-03-11 Genentech Inc Crystallization of anti-VEGF antibodies
MX2007001221A (en) 2004-08-04 2007-03-23 Amgen Inc Antibodies to dkk-1.
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1981910B1 (en) 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
EP2094731A2 (en) 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
WO2008061013A2 (en) 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
US8178099B2 (en) 2006-12-29 2012-05-15 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
JP2010526766A (en) 2007-02-02 2010-08-05 ノバルティス アーゲー Modulators of sclerostin binding partners for treating bone-related disorders
CN101646457B (en) 2007-03-20 2013-05-01 伊莱利利公司 Anti-sclerostin antibodies
AU2008233173B2 (en) 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
TWI489993B (en) 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin
WO2009056634A2 (en) 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
BRPI0819688A2 (en) 2007-12-14 2015-06-16 Amgen Inc Process for treating bone fracture with anti-sclerostin antibodies.
BRPI0913406A2 (en) 2008-06-03 2018-01-09 Abbott Lab double variable domain immunoglobulins and their uses
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP2632951B1 (en) 2010-10-27 2017-08-02 Amgen Inc. Dkk1 antibodies and methods of use
EA202091676A1 (en) 2011-12-28 2021-01-29 Эмджен Инк. METHOD FOR TREATMENT OF BONE MASS LOSS OF ALVEOLAR PROCESSING BY APPLICATION OF ANTIBODIES TO SCLEROSTIN

Also Published As

Publication number Publication date
US9920114B2 (en) 2018-03-20
TW201247703A (en) 2012-12-01
CA2830538C (en) 2020-05-12
IL228455A (en) 2017-05-29
PE20140437A1 (en) 2014-04-17
US20170210792A1 (en) 2017-07-27
ZA201608660B (en) 2018-05-30
SG193610A1 (en) 2013-11-29
US20160083460A1 (en) 2016-03-24
US9617333B2 (en) 2017-04-11
MX338078B (en) 2016-04-01
IL228455A0 (en) 2013-12-31
ZA201307122B (en) 2017-08-30
CA2830538A1 (en) 2012-10-04
US20140105909A1 (en) 2014-04-17
AR085575A1 (en) 2013-10-09
PH12013501971B1 (en) 2018-08-31
EA029956B1 (en) 2018-06-29
SG10201701634PA (en) 2017-04-27
AU2012236962B2 (en) 2017-05-11
EA201391389A1 (en) 2014-03-31
JP2014511842A (en) 2014-05-19
EP2688910B1 (en) 2019-05-29
TN2013000378A1 (en) 2015-01-20
NZ615624A (en) 2015-10-30
AP2013007135A0 (en) 2013-09-30
AU2012236962A1 (en) 2013-10-10
CN103517920A (en) 2014-01-15
US9145457B2 (en) 2015-09-29
MY170720A (en) 2019-08-27
KR20140018315A (en) 2014-02-12
JP2017125020A (en) 2017-07-20
PH12013501971A1 (en) 2014-01-06
WO2012135035A1 (en) 2012-10-04
CN103517920B (en) 2018-04-17
EP2688910A1 (en) 2014-01-29
MX2013011012A (en) 2014-04-25
JP6412964B2 (en) 2018-10-24
MA35009B1 (en) 2014-04-03
BR112013024493A2 (en) 2018-06-26
CL2013002743A1 (en) 2014-05-23
CO6801637A2 (en) 2013-11-29
AP3981A (en) 2017-01-05

Similar Documents

Publication Publication Date Title
CR20160147A (en) FORMULATIONS OF ANTIBODIES
ECSP14005975A (en) Anti-PHF-tau antibodies and their uses
CO6771458A2 (en) Antibody-drug conjugates
UY34228A (en) STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
MX2019002979A (en) FORMULATIONS OF ANTIBODIES.
CR20120215A (en) ANTIBODIES AGAINST HUMAN CSF-1R AND USES OF THE SAME
CR20150502A (en) SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP AND DR5, SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
ECSP12012221A (en) ANTI-CD40 ANTIBODIES
UY34404A (en) STABLE ANTIBODY UNITED TO MULTIPLE ANTIGENS
CL2016001732A1 (en) Synthetic methods for spiro-oxoindole compounds (div. Sol. 3633-13).
UY34456A (en) ANTI-IL-36R ANTIBODIES
UY34537A (en) COMPOSITIONS AND METHODS FOR ANTIBODIES ACTING ON FACTOR P
CR20150049A (en) ANTI-CD79B ANTIBODIES AND IMMUNOCATION
UY34394A (en) ANTIBODY POLIPEPTIDES ANTAGONIZING CD40L
MX2019008065A (en) Compositions comprising anti-cd38 antibodies and lenalidomide.
UY34206A (en) INTERLEUCINE MONOCLONAL ANTIBODY-31
CR20140212A (en) ANTI-HTRA1 ANTIBODIES AND METHODS OF USE
EA201391274A1 (en) AMINOHINOLINES AS KINAZ INHIBITORS
UY34271A (en) ANTI-TIE2 ANTIBODIES AND USES OF THE SAME
AR095348A1 (en) CELL CULTURE MEDIA AND ANTIBODY PRODUCTION METHODS
CR20140121A (en) FORMULATIONS FOR RICE FIELDS
CR20140124A (en) TRANSCLOMIFEN METABOLITES AND USES OF THE SAME
UY34842A (en) STABILIZED FORMULATIONS CONTAINING ANTI-DLL4 ANTIBODIES
ECSP13012914A (en) SYNTHESIS OF DERIVATIVES OF 2-CARBOXAMIDA-CICLOAMINO-UREA
ECSP11011190A (en) ANTI-RHD MONOCLONAL ANTIBODIES